01 — At a Glance
The Pharma Player Who Swallowed a Whale
- 52-Week High / Low₹4,470 / ₹3,028
- Q3 FY26 Revenue₹3,303 Cr
- Q3 FY26 PAT₹635 Cr
- Q3 FY26 EPS₹18.76
- Annualised EPS (Q3×4)₹75.04
- Book Value per Share₹250
- Price to Book17.3x
- Dividend Yield0.67%
- Debt₹2,822 Cr
- JB Pharma Deal Size₹11,917 Cr
Auditor’s Gasp: Torrent closed Q3 FY26 with ₹3,303 crore revenue (+18% YoY) and ₹635 crore PAT (+27.6% YoY). Standalone profits up nearly 28%. Then they announced a ₹11,917 crore acquisition of JB Pharma—a company with a legitimate portfolio but also a legacy of being in PE’s crosshairs. Interim dividend of ₹29/share announced Feb 13, 2026. Market rewarded this chaos with a +14% three-month return. Risk appetite: *chef’s kiss*.
02 — Introduction
The Indian Pharma Company That Just Became Bigger. Overnight.
Torrent Pharmaceuticals is not a household name unless your household involves pharmacology discussions at the dinner table. But if you’ve ever swallowed a pill for high cholesterol, diabetes, or indigestion, there’s a non-trivial chance it was one of Torrent’s branded generics. They’ve been quietly winning India’s domestic formulations market for decades—seventh largest player, ₹5 out of every ₹100 in chronic therapies spend, 16 brands with over ₹100 crore annual revenues each. Boring? Yes. Profitable? Extremely.
Then, on November 7, 2025, Torrent’s board approved a ₹11,917 crore acquisition of 46.39% of JB Chemicals & Pharmaceuticals from KKR’s Tau Investments. The deal closed on January 21, 2026. JB is an older, more diversified pharma company with presence in Brazil, Russia, Germany, and the US. Combined, the two will be India’s third-largest by revenue (roughly). Management swears there will be no disruption. Wall Street swears the synergies will be ₹400–450 crore over 2–3 years. Everyone else is asking: why take on ₹12,000+ crore debt when you already have a beautiful, debt-light business?
Welcome to the “strategic pharma consolidation wave” that everyone saw coming but nobody really wanted. And yet, here we are. Torrent delivered an excellent standalone Q3 result. JB will start consolidating from Q4 FY26 (January 21 onwards). The merged entity is expected to complete integration by Q1 FY28 (post NCLT approval, which is still pending). In the meantime, management has a CFO for JB, a separate CEO for JB, and a very polished line: “we expect Q1 onwards, they should be back on track.” Translation: Q4 might be messy.
Concall Note (Feb 2026): Management flagged cost synergies of ₹400–450 crore over 2–3 years, but explicitly stated: “synergy number does not include either of these” (Novartis in-licensed Ophthal portfolio and Asmarda). They also corrected investors: “JB EBITDA margin is closer to 28–29%” (not 18–19%). Translation: analysts were running backward models. Management is being transparent. Applause, but with caveats.
03 — Business Model: Generics That Actually Earn Money
Branded Generics in India. Cheap Molecules That Print Margins.
Torrent’s business is aggressively unsexy: manufacture and sell generic pharmaceutical formulations under Torrent’s own brands in India (53% of FY24 revenue) and key international markets—Brazil (10%), Germany (10%), USA (10%), and others (17%). Revenue for FY25 was ₹11,516 crore. Margins sit at 32–33% operating profit margin, consistently. No volatility. No innovation theater. Just cost discipline and distribution.
Segmentation is 74% branded generics, 26% generic actives. The branded generics are split across India (domestic chronic/sub-chronic therapies) and Brazil (also branded generics). The 26% is export-oriented—USA generics, Germany generics via tenders, and a legacy trade generics business that management is now calling “structurally unattractive” and plans to exit or consolidate.
Manufacturing footprint: 8 facilities in India with 2,500+ crore unit-dose capacity and 90 MTPA API capacity. R&D spend is 5–6% of revenue (₹575–687 crore annually). Patents granted: 684 out of 1,274 applications. New product launches average 5–7 per year in the US generics segment; in India, it’s volume-driven with mix expansion in higher-margin chronic therapies.
India Market Share7th RankIPM Position
Chronic Therapies~76%Revenue Mix
Branded to Generics74%Split
OPM Consistency32–33%4 Years
The Acquistion Move: So why did Torrent buy JB? JB is bigger (₹12,742 crore revenue in FY25), more diversified geographically (strong in Russia, East Africa, Middle East), and has a higher leverage profile (₹2,822 crore debt, Debt/Equity 0.33x). Combined, Torrent+JB becomes India’s third-largest pharma by revenue. Torrent gets JB’s geographic reach + product portfolio (especially Ophthal from Novartis in-licensing). JB gets Torrent’s operational discipline and margin expansion playbook. Synergies are immediate—consolidated procurement, shared field force, elimination of JB’s “run-at-zero margin” trade generics business. But the debt integration is the wild card.
💬 If Torrent’s standalone business is so pristine, why not just keep compounding it? Drop your thoughts on whether this JB acquisition is brilliant M&A or overconfidence.
04 — Financials Overview
Q3 FY26: The Numbers (Torrent Standalone)
Result type: Quarterly Results | Q3 FY26 EPS: ₹18.76 | Annualised EPS (Q3×4): ₹75.04
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 3,303 | 2,809 | 3,302 | +17.6% | +0.0% |
| Operating Profit | 1,088 | 914 | 1,083 | +19.0% | +0.5% |
| OPM % | 32.9% | 32.5% | 32.8% | +40 bps | +10 bps |
| PAT | 635 | 503 | 591 | +26.2% | +7.4% |
| EPS (₹) | 18.76 | 14.86 | 17.46 | +26.2% | +7.4% |
Recalculation Check: FY26 full-year EPS will be declared in March. For now, annualising Q3 FY26 EPS of ₹18.76 × 4 = ₹75.04. Current CMP ₹4,318 ÷ ₹75.04 = P/E of 57.5x (annualised basis). But wait—the screener shows P/E of 63.4x. That’s because the screener is using **TTM EPS of ₹67.1**, which includes results from Mar 2025, Jun 2025, Sep 2025, and Dec 2025 combined = FY25 full-year + Q3 FY26. The P/E difference reflects the transition period. Once Q4 FY26 closes (Mar 31, 2026), P/E will reset. Expect some denominator volatility here.
05 — Valuation Discussion
What’s Fair Value When You’re Buying At Peak P/E?
Join 10,000+ investors who read this every week.
